BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 23277329)

  • 1. The Fc-engineered CD19 antibody MOR208 (XmAb5574) induces natural killer cell-mediated lysis of acute lymphoblastic leukemia cells from pediatric and adult patients.
    Kellner C; Zhukovsky EA; Pötzke A; Brüggemann M; Schrauder A; Schrappe M; Kneba M; Repp R; Humpe A; Gramatzki M; Peipp M
    Leukemia; 2013 Jul; 27(7):1595-8. PubMed ID: 23277329
    [No Abstract]   [Full Text] [Related]  

  • 2. CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody.
    Awan FT; Lapalombella R; Trotta R; Butchar JP; Yu B; Benson DM; Roda JM; Cheney C; Mo X; Lehman A; Jones J; Flynn J; Jarjoura D; Desjarlais JR; Tridandapani S; Caligiuri MA; Muthusamy N; Byrd JC
    Blood; 2010 Feb; 115(6):1204-13. PubMed ID: 19965644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia.
    Horton HM; Bernett MJ; Pong E; Peipp M; Karki S; Chu SY; Richards JO; Vostiar I; Joyce PF; Repp R; Desjarlais JR; Zhukovsky EA
    Cancer Res; 2008 Oct; 68(19):8049-57. PubMed ID: 18829563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of Fc engineering on an anti-CD19 antibody: increased Fcgamma receptor affinity enhances B-cell clearing in nonhuman primates.
    Zalevsky J; Leung IW; Karki S; Chu SY; Zhukovsky EA; Desjarlais JR; Carmichael DF; Lawrence CE
    Blood; 2009 Apr; 113(16):3735-43. PubMed ID: 19109559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. XmAb-5574 antibody demonstrates superior antibody-dependent cellular cytotoxicity as compared with CD52- and CD20-targeted antibodies in adult acute lymphoblastic leukemia cells.
    Rafiq S; Cheney C; Mo X; Jarjoura D; Muthusamy N; Byrd JC
    Leukemia; 2012 Jul; 26(7):1720-2. PubMed ID: 22333878
    [No Abstract]   [Full Text] [Related]  

  • 6. An Fc-engineered CD19 antibody eradicates MRD in patient-derived
    Schewe DM; Alsadeq A; Sattler C; Lenk L; Vogiatzi F; Cario G; Vieth S; Valerius T; Rosskopf S; Meyersieck F; Alten J; Schrappe M; Gramatzki M; Peipp M; Kellner C
    Blood; 2017 Sep; 130(13):1543-1552. PubMed ID: 28698205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Macrophage and NK-mediated killing of precursor-B acute lymphoblastic leukemia cells targeted with a-fucosylated anti-CD19 humanized antibodies.
    Matlawska-Wasowska K; Ward E; Stevens S; Wang Y; Herbst R; Winter SS; Wilson BS
    Leukemia; 2013 Jun; 27(6):1263-74. PubMed ID: 23307031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persuading natural killer cells to eliminate bad B cells.
    Cooper LJ
    Clin Cancer Res; 2009 Aug; 15(15):4790-1. PubMed ID: 19638468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimeric CD19 antibody mediates cytotoxic activity against leukemic blasts with effector cells from pediatric patients who received T-cell-depleted allografts.
    Lang P; Barbin K; Feuchtinger T; Greil J; Peipp M; Zunino SJ; Pfeiffer M; Handgretinger R; Niethammer D; Fey GH
    Blood; 2004 May; 103(10):3982-5. PubMed ID: 14764538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts.
    Feucht J; Kayser S; Gorodezki D; Hamieh M; Döring M; Blaeschke F; Schlegel P; Bösmüller H; Quintanilla-Fend L; Ebinger M; Lang P; Handgretinger R; Feuchtinger T
    Oncotarget; 2016 Nov; 7(47):76902-76919. PubMed ID: 27708227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Marshaling the immune system to eliminate minimal residual disease in B-ALL.
    Hede K
    J Natl Cancer Inst; 2014 Sep; 106(9):. PubMed ID: 25214564
    [No Abstract]   [Full Text] [Related]  

  • 12. Reduction of Minimal Residual Disease in Pediatric B-lineage Acute Lymphoblastic Leukemia by an Fc-optimized CD19 Antibody.
    Seidel UJ; Schlegel P; Grosse-Hovest L; Hofmann M; Aulwurm S; Pyz E; Schuster FR; Meisel R; Ebinger M; Feuchtinger T; Teltschik HM; Witte KE; Schwarze CP; Rammensee HG; Handgretinger R; Jung G; Lang P
    Mol Ther; 2016 Sep; 24(9):1634-43. PubMed ID: 27380762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effective lysis of lymphoma cells with a stabilised bispecific single-chain Fv antibody against CD19 and FcgammaRIII (CD16).
    Bruenke J; Barbin K; Kunert S; Lang P; Pfeiffer M; Stieglmaier K; Niethammer D; Stockmeyer B; Peipp M; Repp R; Valerius T; Fey GH
    Br J Haematol; 2005 Jul; 130(2):218-28. PubMed ID: 16029450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical activity of the antibody-drug conjugate denintuzumab mafodotin (SGN-CD19A) against pediatric acute lymphoblastic leukemia xenografts.
    Jones L; McCalmont H; Evans K; Mayoh C; Kurmasheva RT; Billups CA; Houghton PJ; Smith MA; Lock RB
    Pediatr Blood Cancer; 2019 Aug; 66(8):e27765. PubMed ID: 31012549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
    Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
    MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TRAIL-mediated killing of acute lymphoblastic leukemia by plasmacytoid dendritic cell-activated natural killer cells.
    Lelaidier M; Dìaz-Rodriguez Y; Cordeau M; Cordeiro P; Haddad E; Herblot S; Duval M
    Oncotarget; 2015 Oct; 6(30):29440-55. PubMed ID: 26320191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL.
    Woyach JA; Awan F; Flinn IW; Berdeja JG; Wiley E; Mansoor S; Huang Y; Lozanski G; Foster PA; Byrd JC
    Blood; 2014 Dec; 124(24):3553-60. PubMed ID: 25301708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CAR T-cell therapy effective in B acute lymphoblastic leukaemia.
    Wang M
    Lancet Oncol; 2017 Jun; 18(6):e314. PubMed ID: 28528746
    [No Abstract]   [Full Text] [Related]  

  • 19. Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival.
    Oelsner S; Wagner J; Friede ME; Pfirrmann V; Genßler S; Rettinger E; Buchholz CJ; Pfeifer H; Schubert R; Ottmann OG; Ullrich E; Bader P; Wels WS
    Int J Cancer; 2016 Oct; 139(8):1799-809. PubMed ID: 27253354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoclonal antibodies in adult acute lymphoblastic leukemia.
    Kantarjian H
    Hematology; 2012 Apr; 17 Suppl 1():S52-4. PubMed ID: 22507779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.